Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). It has been studied in randomized, double-blind, placebo-controlled human trials published in peer-reviewed journals.
Established: tesamorelin is a synthetic analog of growth hormone-releasing factor (GHRH), which acts at pituitary GHRH receptors to stimulate growth hormone release [1].
| Study | Model | Reported result | Source |
|---|---|---|---|
| Randomized trial with safety extension [1] | Human 404 adults, randomized 2:1, double-blind, placebo-controlled, 6 months plus 6-month re-randomized extension | Primary endpoint: imaging measure (see publication). Published. | Peer-reviewed J Acquir Immune Defic Syndr 2010 |
| Visceral and liver fat trial [2] | Human 50 adults, randomized, double-blind, placebo-controlled, 6 months | Primary endpoints: imaging measures (see publication). Published. | Peer-reviewed JAMA 2014 |
Human trials are listed for research context only; outcomes are reported in the linked publications. Animal and lab results do not establish effects in humans.
PureLab does not supply this compound. This page summarizes published research only.
